Hospital
Anna Jaques Hospital
Anna Jaques Hospital was paid $1.35M by Medicaid between Mar 2018 and Nov 2020, across 113 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoANNA JAQUES HOSPITAL
NEWBURYPORT, MA 01950
NEWBURYPORT, MA 01950
33aNPI1619061769assigned 10/03/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$1.35M
24GClaims47,363
24DCodes billed113
24AFirst – last monthMar 2018 – Nov 2020
Compared with peers
Next to other Psychiatric Hospital Unit providers in Massachusetts
Rank by total paid#9 of 27
Median peer was paid$138K
This provider vs. median9.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,229 | $546K | |
| 2019 | 10,217 | $283K | |
| 2020 | 18,917 | $517K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 1,002 | 953 | $187K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 824 | 789 | $170K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.3% | 585 | 562 | $112K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.4% | 487 | 465 | $73K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.6% | 944 | 869 | $48K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 2.7% | 362 | 362 | $37K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.7% | 432 | 353 | $36K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.5% | 367 | 116 | $34K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.4% | 768 | 768 | $33K |
| 80053 | Comprehensive metabolic panel | 2.4% | 2,591 | 2,427 | $33K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.4% | 327 | 314 | $32K |
| 76830 | Ultrasound, transvaginal | 2.3% | 282 | 282 | $31K |
101 more codes
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.3% | 216 | $31K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.2% | 461 | $30K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 4,381 | $28K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.0% | 1,811 | $27K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.8% | 740 | $24K |
| 71046 | Radiologic examination, chest; 2 views | 1.8% | 614 | $24K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.6% | 1,190 | $21K |
| 99441 | 1.5% | 138 | $21K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.5% | 740 | $20K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.3% | 346 | $17K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.2% | 124 | $17K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 149 | $16K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.1% | 251 | $15K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.1% | 331 | $14K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 1,529 | $14K |
| 80061 | Lipid panel | 1.0% | 2,328 | $14K |
| 99219 | <1% | 16 | $12K | |
| 86803 | <1% | 468 | $12K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 61 | $10K |
| 87480 | <1% | 381 | $8K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 30 | $8K |
| 80050 | General health panel | <1% | 500 | $8K |
| 87510 | <1% | 381 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 977 | $7K |
| 87660 | <1% | 381 | $7K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 54 | $6K |
| 82728 | <1% | 255 | $6K | |
| 84439 | <1% | 602 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 79 | $5K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 25 | $5K |
| 82607 | <1% | 313 | $4K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 24 | $4K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 59 | $4K |
| 80076 | <1% | 868 | $4K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 44 | $3K |
| 76801 | <1% | 12 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,547 | $3K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 32 | $3K |
| 84484 | <1% | 300 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 108 | $2K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 28 | $2K |
| 81003 | <1% | 1,170 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 13 | $2K |
| 87340 | <1% | 165 | $2K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 588 | $2K |
| 83690 | <1% | 401 | $2K | |
| 83550 | <1% | 123 | $2K | |
| 80081 | <1% | 25 | $2K | |
| 86618 | <1% | 116 | $2K | |
| 86706 | <1% | 146 | $2K | |
| 82043 | <1% | 299 | $2K | |
| 87070 | <1% | 244 | $2K | |
| 84481 | <1% | 94 | $2K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 18 | $1K |
| 83540 | <1% | 196 | $1K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 12 | $1K |
| 81001 | <1% | 514 | $1K | |
| 86704 | <1% | 87 | $1K | |
| 87522 | Neg quan hep c or qual rna | <1% | 27 | $1K |
| 84702 | <1% | 93 | $1K | |
| 86709 | <1% | 56 | $1K | |
| 97161 | <1% | 12 | $1K | |
| 81025 | <1% | 268 | $1K | |
| 99217 | <1% | 12 | $900.00 | |
| 83735 | <1% | 160 | $850.91 | |
| 87186 | <1% | 100 | $836.88 | |
| 82746 | <1% | 52 | $802.47 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 437 | $797.00 |
| 85651 | <1% | 226 | $760.54 | |
| 94761 | <1% | 146 | $720.00 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 28 | $656.88 |
| 87077 | <1% | 66 | $589.60 | |
| 86038 | <1% | 42 | $570.78 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 236 | $550.00 |
| 83520 | <1% | 13 | $538.35 | |
| 86140 | <1% | 106 | $497.14 | |
| 85610 | <1% | 145 | $466.24 | |
| J2704 | Injection, propofol, 10 mg | <1% | 557 | $378.04 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 541 | $306.89 |
| 82950 | <1% | 31 | $302.79 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 96 | $268.71 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 341 | $248.04 |
| 86592 | <1% | 51 | $212.04 | |
| 82565 | <1% | 49 | $172.72 | |
| 86430 | <1% | 25 | $159.50 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 185 | $118.33 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 149 | $110.36 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 384 | $94.63 |
| 82570 | <1% | 17 | $89.68 | |
| 86850 | <1% | 24 | $86.64 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 97 | $86.64 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 56 | $69.00 |
| 86900 | <1% | 26 | $62.86 | |
| 86901 | <1% | 26 | $62.86 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 26 | $54.95 |
| 82948 | <1% | 35 | $35.74 | |
| 84703 | <1% | 14 | $15.50 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 243 | $0.00 |
| 84520 | 0% | 30 | $0.00 | |
| 94760 | 0% | 45 | $0.00 | |
| 71045 | Radiologic examination, chest; single view | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialOCONNOR, DELIA (PRESIDENT & CFO)
| Provider | Location | Paid |
|---|---|---|
| Anna Jaques Hospital | Newburyport, MA | $12.84M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.